Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm00328a012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incomplete remyelination via therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function.
Nat Commun
January 2025
Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, CO, USA.
Myelin loss induces neural dysfunction and contributes to the pathophysiology of neurodegenerative diseases, injury conditions, and aging. Because remyelination is often incomplete, better understanding endogenous remyelination and developing remyelination therapies that restore neural function are clinical imperatives. Here, we use in vivo two-photon microscopy and electrophysiology to study the dynamics of endogenous and therapeutic-induced cortical remyelination and functional recovery after cuprizone-mediated demyelination in mice.
View Article and Find Full Text PDFThyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom.
J Gastroenterol Hepatol
January 2025
Department of Pharmacology, Hepatology and Molecular Medicine Lab, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India.
Background: Resmetirom, the first FDA-approved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined with lifestyle modifications, improves NASH resolution and reduces fibrosis by at least one stage. Low thyroid hormone (T) levels are linked to a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). Epidemiological studies have confirmed the positive correlation between hypothyroidism and MASLD.
View Article and Find Full Text PDFThyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
J Hepatol
October 2024
Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands. Electronic address:
The association between suboptimal thyroid function ((sub)clinical hypothyroidism or low-normal thyroid function) and the metabolic syndrome and MASLD (metabolic dysfunction-associated steatotic liver disease) has been clearly established. Furthermore, in MASLD, intracellular thyroid hormone concentrations are low and the activation of the thyroid hormone receptor (THR) is reduced. Administration of thyroid hormone has been shown to reduce liver triglycerides by stimulating fatty acid disposal through lipophagy and beta-oxidation, and to lower LDL-cholesterol.
View Article and Find Full Text PDFActions of thyroid hormones and thyromimetics on the liver.
Nat Rev Gastroenterol Hepatol
January 2025
Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore.
Thyroid hormones (triiodothyronine and thyroxine) are pivotal for metabolic balance in the liver and entire body. Dysregulation of the hypothalamus-pituitary-thyroid axis can contribute to hepatic metabolic disturbances, affecting lipid metabolism, glucose regulation and protein synthesis. In addition, reductions in circulating and intrahepatic thyroid hormone concentrations increase the risk of metabolic dysfunction-associated steatotic liver disease by inducing lipotoxicity, inflammation and fibrosis.
View Article and Find Full Text PDFPharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Expert Opin Pharmacother
June 2024
Department of Hepatology & Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) involves fatty liver disease linked to conditions like obesity and diabetes, which can lead to more severe liver issues like inflammation and fibrosis.
- The FDA has approved a new drug, resmetirom, as the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, with ongoing research into its effectiveness and other potential therapies.
- Despite the promising approval of resmetirom, challenges remain in understanding MASLD's complexity, and future developments may focus on combination therapies and tailored treatments for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!